2cureX AB Logo

2cureX AB

Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.

2CUREX | ST

Overview

Corporate Details

ISIN(s):
SE0010468124
LEI:
549300SFOL75WIYF2O80
Country:
Sweden
Address:
Box 159, 261 22 Landskrona
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

2cureX AB is a biotechnology company specializing in precision oncology through functional drug sensitivity testing. The company develops and commercializes the IndiTreat® family of tests, its core product line. IndiTreat® is the first CE-marked in-vitro diagnostic (IVD) test that utilizes patient-derived 3D tumoroids to predict individual responses to cancer treatments. This technology provides oncologists with personalized data to guide therapy selection, particularly for patients with metastatic colorectal cancer. The company's mission is to improve cancer treatment outcomes by matching specific therapies to individual patients, thereby enhancing the efficacy of oncological care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all 2cureX AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 2cureX AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 2cureX AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MAINZ BIOMED N.V. Logo
Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.
United States of America MYNZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.